Treatment with carfilzomib, daratumumab, and dexamethasone (KdD) may be a viable therapeutic option for patients with multiple myeloma who have become refractory to other treatments or have had a relapse, according to an article published in The Lancet Oncology .

The updated analysis of the randomised, multicentre, open-label, phase 3...